Livers of MASLD Patients End Up Less Fatty With Novel Injectable

(MedPage Today) — WASHINGTON — A large percentage of people with metabolic dysfunction-associated steatotic liver disease (MASLD) had their liver fat content normalize with an investigational dual agonist of the GLP-1 and glucagon receptors…